 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
35 News |  |
- | MIS416 / Amplia Therap
Journal: Innate Signaling in the CNS Prevents Demyelination in a Focal EAE Model. (Pubmed Central) - Jun 22, 2021
Moreover, intrathecal MIS416 altered the composition of early CNS infiltrates, increasing proportions of myeloid and NK cells and reducing T cells at the lesion site. This study contributes to an increased understanding of how innate immune responses can play a protective role, which in turn may lead to additional therapeutic strategies for the prevention and treatment of demyelinating pathologies.
- | MIS416 / Amplia Therap
Journal, IO biomarker: Innate signaling within the central nervous system recruits protective neutrophils. (Pubmed Central) - Dec 30, 2020
In contrast to intrathecal administration, intravenous administration of MIS416 led to monocyte but not neutrophil infiltration to the CNS. We thus identify a CNS-intrinsic and -specific phagocytosis-induced recruitment of anti-inflammatory neutrophils that contribute to CNS homeostasis and may have therapeutic potential.
- | MIS416 / Amplia Therap
Journal: TLR9-dependent interferon production prevents group 2 innate lymphoid cell-driven airway hyperreactivity. (Pubmed Central) - May 31, 2020
TLR9 activation alleviates ILC2-driven AHR and airway inflammation through direct suppression of cell function. Microparticle-based delivery of TLR9 ligands may serve as a therapeutic strategy for asthma treatment.
- || MIS416 / Innate
Clinical, P1 data, Clinical Trial,Phase I, Journal: First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. (Pubmed Central) - Apr 21, 2020
In a preclinical study, adding anti-PD-1 monoclonal antibody to CHP-NY-ESO-1 and MIS416 induced significant tumor suppression. This combination therapy is a promising next step.
- MIS416 / Innate
Differential monocytic response patterns to MIS416 in vitro during progressive multiple sclerosis and the involvement of NF-kB. (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_1593;
These findings support a central role for NF-kB pathway mutations in regulating monocyte responses to MIS416. Overall, this work indicates that MIS416 therapy has the potential to modulate peripheral immune responses through substantive TF and cytokine induction, which can alter the immune milieu following in vivo treatment.
- | MIS416 / Amplia Therap
Enrollment change, Trial withdrawal: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - May 1, 2018
P1, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Overall, this work indicates that MIS416 therapy has the potential to modulate peripheral immune responses through substantive TF and cytokine induction, which can alter the immune milieu following in vivo treatment. N=12 --> 0 | Recruiting --> Withdrawn
- | MIS416 / Amplia Therap
Enrollment open: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 28, 2017
P1, N=12, Recruiting, Sponsor: Roswell Park Cancer Institute
N=12 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- |||| MIS416 / Amplia Therap
Trial completion: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jul 17, 2017
P2b, N=93, Completed, Sponsor: Innate Immunotherapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | MIS416 / Amplia Therap
Trial primary completion date: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jun 2, 2017
P1, N=12, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Aug 2018
- MIS416 / Amplia Therap
New P1 trial: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jul 14, 2016
P1, N=12, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- ||| MIS416 / Amplia Therap
Enrollment closed, Trial primary completion date: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Apr 26, 2016
P2b, N=93, Active, not recruiting, Sponsor: Innate Immunotherapeutics
Trial primary completion date: Aug 2017 --> Aug 2018 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Mar 2017
- MIS416 / Amplia Therap
Trial primary completion date: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jan 18, 2015
P2b, N=90, Recruiting, Sponsor: Innate Immunotherapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Mar 2017 Trial primary completion date: Dec 2015 --> May 2016
- | MIS416 / Amplia Therap
New P2b trial: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 29, 2014
P2b, N=90, Recruiting, Sponsor: Innate Immunotherapeutics
- | MIS416 / Amplia Therap
Enrollment change, Immunomodulating: Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=34, Completed, Sponsor: Innate Therapeutics Limited
Trial primary completion date: Dec 2015 --> May 2016 N=24 --> 34
- | MIS416 / Amplia Therap
Trial completion, Immunomodulating: Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=34, Completed, Sponsor: Innate Therapeutics Limited
N=24 --> 34 Active, not recruiting --> Completed